This invention provides a method for treating or for reducing ambulatory deterioration in a human patient diagnosed to be afflicted with relapsing-remitting multiple sclerosis (RRMS) and having a high baseline disability score according to the Kurtzke Expanded Disability Status Scale (EDSS), comprising periodically administering to only the patient diagnosed with RRMS and having a high baseline disability score an amount of laquinimod effective to treat the patient or to reduce ambulatory deterioration. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a human patient diagnosed to be afflicted with RRMS and having a high baseline disability score according to the EDSS.本發明提供用於治療或減輕經診斷患有復發緩解型多發性硬化症(RRMS)且根據Kurtzke擴展失能狀態量表(EDSS)具有高基線失能評分之人類病患的步行劣化之方法，其包含僅向經診斷患有RRMS且具有高基線失能評分之該病患週期性投與有效治療該病患或減輕步行劣化之量的拉發利莫(laquinimod)。本發明進一步提供包含有效量之拉發利莫之醫藥組合物及包裝，其用於治療經診斷患有RRMS且根據該EDSS具有高基線失能評分之人類病患。
